Antibody drugs represent a highly promising class of therapies and have witnessed substantial growth with the approval of new drugs for diverse diseases. Recent advancements in antibody discovery technologies have led to the emergence of numerous novel antibody therapeutics. Historically, antibodies were discovered through established in vivo immunization procedures or in vitro antibody library screening methods. However, the escalating costs and relatively high failure rates associated with traditional drug discovery approaches have underscored the pressing need for in-silico methods, particularly structure-guided approaches. The expansion of data repositories, encompassing protein structures, sequences, and NGS, has significantly augmented the availability of extensive data for antibody discovery. The accessibility of such datasets can profoundly impact the streamlining of the antibody discovery process. Tsingke provides a one-stop service platform from gene to antibody expression to meet extensive needs for specific applications.
